clinical trial · NCT07349329
A Study to Evaluate the Efficacy and Safty of 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA)
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.·phase3·not yet recruiting·n = 380
Axial Spondyloarthritis, Non-Radiographic608Placebo
brief summary
This study will evaluate the efficacy and safety of 608 in patients with nr-axSpA.
started
Mar 9, 2026
primary completion
Apr 19, 2028
completion
Feb 21, 2029
last updated
Jan 16, 2026
detailed description
The purpose of this study is to demonstrate the clinical efficacy, safety of 608 compared to placebo in patients with nr-axSpA.
official title
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of 608 in Patients With Non-radiographic Axial Spondyloarthritis (Nr-axSpA)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol